Kidney Cancer Drugs Market Growth Accelerates: Strategic Forecast Predicts $10.48 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Kidney Cancer Drugs Market Size Growth Forecast: What to Expect by 2025?
In the past several years, the market size for kidney cancer drugs has seen robust growth. Expected to rise from $8.2 billion in 2024 to $8.63 billion in 2025, with a compound annual growth rate (CAGR) of 5.1%. The exponential growth during the historic period is due to higher spending on healthcare, a rapidly enlarging elderly population, an increase in pharmaceutical research and development expenditure, and progress in the discovery of cancer drugs.

How Will the Kidney Cancer Drugs Market Size Evolve and Grow by 2029?
In the forthcoming years, the market size for kidney cancer drugs is projected to witness a consistent growth, escalating to $10.48 billion by 2029, with a compound annual growth rate (CAGR) of 5.0%. This surge within the forecast time frame can be credited to factors such as an expanding elderly population, increased spending on healthcare, a rise in strategic partnerships and acquisitions for medicine formulation, and the vast potential of developing economies. Noteworthy trends anticipated for the forecast period comprise embracing 3D technology in drug production and modelling, capital infusion into biomarkers, initiation or acceptance of novel treatment advancements, enhancement of treatment through personalized medicine, investment in artificial intelligence solutions, and affiliations and partnerships with other firms or governmental entities to fast-track the creation of new medicines.

View the full report here:
https://www.thebusinessresearchcompany.com/report/kidney-cancer-drugs-global-market-report

What Drivers Are Propelling the Growth of Kidney Cancer Drugs Market Forward?
One of the main motivators for the progression of the kidney cancer drugs market is the escalating rate of renal cancer. Lifestyles changes, tobacco use, and unhealthy eating practices are few of the elements that aid in the expansion of these renal cancer cells. For example, the American Cancer Society, a health organization located in the U.S., projected in January 2022 that there will be 79,000 new cases of kidney cancer (50,290 men and 28,710 women), and the disease will result in 13,920 deaths (8,960 men and 4,960 women). Most diagnoses fall between the ages of 65 and 74 with the mean age being 64. Kidney cancer is relatively unusual under the age of 45. Consequently, this propels the development of the kidney cancer medications market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2591&type=smp

Which Emerging Trends Are Transforming the Kidney Cancer Drugs Market in 2025?
In an effort to advance innovation in cancer care, make treatments more affordable, and widen patient access, leading businesses in the kidney cancer drugs market are leveraging technologies such as the development of biosimilars. This pertains to the creation of biological medicines that closely resemble an already authorized reference product, promising equal efficacy, safety, and quality. For example, Amneal Pharmaceuticals Inc., a pharmaceutical company based in the US, introduced RELEUKO (filgrastim-ayow) in November 2022. This biosimilar to Neupogen (filgrastim), engineered by Amneal Pharmaceuticals, is intended for neutropenia treatment, especially for patients undergoing chemotherapy.

What Are the Key Segments in the Kidney Cancer Drugs Market?
The kidney cancer drugs market covered in this report is segmented -

1) By Type: Renal Cell Carcinoma (RCC), Transitional Cell Carcinoma (TCC) Or Urothelial Cell Carcinoma (UCC)
2) By Product: Nexavar (Sorafenib), Sutent (Sunitinib), Afinitor (Everolimus), Votrient (Pazopanib), Avastin (Bevacizumab), Inlyta (Axitinib), Other Products
3) By End Users: Hospitals, Clinics, Research Center, Other End-Users

Subsegments:
1) By Renal Cell Carcinoma (RCC): Targeted Therapies, Immune Checkpoint Inhibitors, Cytokine Therapies
2) By Transitional Cell Carcinoma (TCC) Or Urothelial Cell Carcinoma (UCC): Chemotherapy Agents, Immunotherapy Agents, Antibody-Drug Conjugates (ADCs)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=2591&type=smp

Who Are the Key Players Shaping the Kidney Cancer Drugs Market's Competitive Landscape?
Major companies operating in the kidney cancer drugs market include Pfizer Inc., Novartis AG, ExelixisInc., F. Hoffmann-La Roche AG, Bristol Myers Squibb Company, Bayer AG, Merck & Co., Inc., EUSA Pharma Inc., UroGen Pharma Ltd., Natco Pharma, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc, Otsuka Pharmaceutical Co., Ltd, Daiichi Pharmaceutical and Sankyo, AstraZeneca plc, GlaxoSmithKline plc, Amgen Inc ., Biocon Ltd, Rani Therapeutics, Eli Lilly and Company, Abbvie, Johnson & Johnson, Sanofi, Biogen Inc, AVEO Oncology, Teva Pharmaceutical Industries Ltd., Kitov Pharma Limited, CureTech Ltd., Neopharma

What Geographic Markets Are Powering Growth in the Kidney Cancer Drugs Market?
North America was the largest region in the kidney cancer drugs market in 2024. Middle East is expected to be the fastest-growing region in the global kidney cancer drugs market share during the forecast period. The regions covered in the kidney cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2591

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.